产品
  • 产品
  • 供应商
  • 采购
  • 资讯
  • 会展
首页 制药产品大全 药品制剂 Ambroxol hydroc...

Ambroxol hydrochloride Injection

2025-02-07
成都市

产品详情

Ambroxol hydrochloride Injection
呼吸系统制剂
Ambroxol hydrochloride Injection
北美洲,中/南美洲,西欧,东欧,大洋洲,亚洲,中东,非洲

产品描述

Active ingredients: ambroxol hydrochloride.

Description: Colorless transparent liquid.

Dosage Form: liquid injection.
Strength: 1ml: 7.5mg; 2ml:15mg; 4ml:30mg
Indications:

1. For acute and chronic lung disease with abnormal secretion of sputum and sputum dysfunction. For instance, exacerbation of bronchitis, asthmatic bronchitis and bronchial asthma requiring expectorant treatment;

2. For prevention treatment of respiratory complications after the surgery;

3. For the treatment of IRDS.

Storage: Store below 30℃ keeping an airtight place.
Packaging: Brown glass ampoule, 5 bottles/box; 10 bottles/box; 20 bottles/box (Can be customized based on customer's order.)
Shelf Life: 36 months

Dosage and Administration:

Adult and children over 12 years old: 15mg two or three times a day, severe cases can be increased to 30mg each time.

Children 6-12 years old: 15mg two or three times a day.
Children 2-6 years old: 7.5mg three times a day.

Children under 2 years old: 7.5mg twice a day.

Administrated as a slow intravenous infusion.

 

 

Baiyu provide CDMO service for:

FDFs & APIs
Primary & secondary packaging
Warehousing
Commercial scale, pilot scale, laboratory scale

You are warmly welcomed to contact us for business cooperation.

剂型
Dosage Form

生产线(条)
Production Lines

年产能
Annual Capacity 

注射剂
Injection

8

650,000,000

口服固体制剂
Oral Solid

3

700,000,000

原料药和中间体
API & Intermediates

3

8,000 Kg

中药前处理和提取
TCM Extraction

2

5,000,000 Kg 

我们承接CDMO业务,欢迎同行朋友来电合作,了解详情。

四川宏明博思药业有限公司
访问店铺
注册资本
公司地址
联系人

公司简介

四川宏明博思药业有限公司成立于2013年,专注于原料药和制剂的生产。现有员工400余人,主要生产高端剂型如注射剂、冻干粉针剂、片剂和胶囊剂。宏明博思的冻干粉针制剂生产线已获得EU GMP,并通过巴西ANVISA现场检查。目前四川宏明博思冻干粉针制剂的多个产品在巴西、智利、秘鲁、危地马拉、泰国、菲律宾、马来西亚、南非、澳大利亚等开展注册中。Sichuan Omnis Pharmaceutical Co., Ltd. was established in 2013, focusing on the manufacture of FDFs and APIs, located in Sichuan Chengdu, China. It currently has more than 400 employees and mainly produces high-end dosage forms such as injections, lyophilized powder injections, tablets and capsules. Omnis has granted China/EU/ANVISA/PICs GMP for lyophilized powder injection line. Currently, multiple products of lyophilized powder injection are undergoing registration in Brazil, Chile, Peru, Guatemala, Thailand, the Philippines, Malaysia, South Africa, Australia, and other countries.
业务类型:
成立日期:
年营业额:
主营产品类别: